Effects of Δ9-THC on VIP-induced prolactin secretion in anterior pituitary cultures: Evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells

Brain Research

Volumn 841, Issue 1-2, 1999, Pages 114-122

  Rodríguez De Fonseca, Fernando ^a   Wenger, Tibor ^b   Navarro, Miguel ^a   Murphy, Laura L ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CAMP; Cannabinoid; CB1 receptor; Lactotroph; Pituitary; Prolactin; Rat; Vasoactive intestinal peptide (VIP)

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; PROLACTIN; TETRAHYDROCANNABINOL; VASOACTIVE INTESTINAL POLYPEPTIDE; DRUG RECEPTOR;

ADENOHYPOPHYSIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; HORMONE BLOOD LEVEL; HORMONE RELEASE; HYPOPHYSIS CELL; IMMUNOCYTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; ANIMAL; BLOOD; CELL CULTURE; CYTOLOGY; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; KINETICS; MALE; METABOLISM; PHYSIOLOGY; SECRETION; SPRAGUE DAWLEY RAT;

ANIMALS; CELLS, CULTURED; CYCLIC AMP; FEMALE; IMMUNOHISTOCHEMISTRY; KINETICS; MALE; PITUITARY GLAND, ANTERIOR; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033546837     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01809-0     Document Type: Article

References (42)

1. Balsa J.A., Sánchez-Franco F., Lorenzo M.J., Pazos F., Lara J.I., Cacicedo L. Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion. Endocrinology. 137:1996;508-513.
2. Ben-Jonathan N. Dopamine: a prolactin inhibiting hormone. Endocrinol. Rev. 6:1985;564-589.
3. Bonhaus D.W., Chang L.K., Kan J., Martin G.R. Dual activation of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonists-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287:1998;884-888.
4. 9-tetrahydrocannabinol on tuberoinfundibular dopamine activity, anterior pituitary sensitivity to dopamine and prolactin release vary as a function of the estrous cycle. Neuroendocrinology. 58:1993;280-286.
5. Chew L.J., Seah V., Murphy D., Carter D. Anterior pituitary vasoactive intestinal peptide mRNA is colocalised with prolactin mRNA in hyperoestrogenised rats. J. Mol. Endocrinol. 16:1996;211-220.
6. Dalcick H., Phelps C.J. Median eminence-afferent vasoactive intestinal peptide (VIP) neurons in the hypothalamus: localization by simultaneous tract tracing and immunocytochemistry. Peptides. 14:1993;1059-1066.
7. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
8. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson R.G., Griffin G., Gibson D., Mandelbaum L.A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
9. Eldridge J.C., Landfield P.W. Cannabinoid interactions with glucocorticoid receptors in rat hippocampus. Brain Res. 534:1990;135-141.
10. 1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther. 284:1998;291-297.
11. 1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics. Biochem. Pharmacol. 53:1997;1919-1927.
12. 9-tetrahydrocannabinol: changes in hypothalamic biogenic amines. Neuroendocrinol. Lett. 14:1992;349-355.
13. Giuffrida A., Parsons L.H., Kehrr A., Rodríguez de Fonseca F.A., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat. Neurosci. 2:1999;358-363.
14. Herkenham M., Lynn A.B., Johnson M.D., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
15. Houston D.B., Howlett A.C. Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonist. Cell. Signalling. 10:1998;667-674.
16. 1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies. Mol. Pharmacol. 53:1998;504-510.
17. Hughes C.L., Everett J.W., Tyrey L. Delta-9-tetrahydrocannabinol suppression of prolactin secretion in the rat: lack of direct pituitary effect. Endocrinology. 109:1981;876-880.
18. Kramer J., Ben-David M. Prolactin suppression by (-)-delta-9-tetrahydro-cannabinol (THC): involvement of serotonergic and dopaminergic pathways. Endocrinology. 103:1978;452-457.
19. Judd A.M. Vasoactive intestinal peptide increases the liberation of arachidonate from anterior pituitary cells in vitro. Life Sci. 57:1995;1641-1646.
20. Mailleux P., Vanderghaen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J. Neurochem. 61:1993;1705-1712.
21. Martín-Calderón J.L., Muñoz R.M., Villanúa M.A., Del Arco I., Moreno J.L., Rodríguez de Fonseca F.A., Navarro M. Characterisation of the acute endocrine actions of HU-210, a potent synthetic cannabinoid in rats. Eur. J. Pharmacol. 344:1998;77-86.
22. Martínez de La Escalera G., Weiner R.I. Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. Endocrine Rev. 13:1992;241-255.
23. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
24. Murphy L.L., Muñoz R.M., Adrian B.A., Villanúa M.A. Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol. Dis. 5:1998;432-446.
25. 9-tetrahydrocannabinol action. Pharmacol. Biochem. Behav. 40:1991;603-608.
26. 9-Tetrahydrocannabinol antagonism of the anterior pituitary response to estradiol in immature female rats. Steroids. 56:1991;97-102.
27. L.L. Murphy, R.W. Steger, A. Bartke, Psychoactive and non psychoactive cannabinoids and their effects on reproductive neuroendocrine parameters, in: R.R. Watson (Ed.), Biochemistry and Physiology of Substance Abuse, Vol. 2, CRC press, Boca Raton, FL, 1990, pp. 73-93.
28. 9-tetrahydrocannabinol, cannabidiol and cannabinol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology. 52:1990;316-321.
29. Nagy G.M., deMaria J.E., Freeman M.E. Changes in the local metabolism of dopamine in the anterior and neural lobes but not in the intermediate lobe of the pituitary gland during nursing. Brain Res. 790:1998;315-317.
30. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport. 8:1997;41-496.
31. 1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1062-1064.
32. Paulssen R.H., Johansen P.W., Gordeladze J.O., Nymoen O., Paulssen E.J., Gautvik K.M. Cell-specific expression and function of adenylyl cyclases in rat pituitary cell lines. Eur. J. Biochem. 222:1994;97-103.
33. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiol. Dis. 5:1998;462-473.
34. Prysor-Jones R.A., Silverlight J.J., Jenkins J.S. Vasoactive intestinal peptide increases intracellular free calcium in rat and human pituitary tumour cells in vitro. J. Endocrinol. 114:1987;119-123.
35. Rettori V., Wenger T., Snyder G., Dalterio S., McCann S.M. Hypothalamic action of delta-9-tetrahydrocannabinol to inhibit the release of prolactin and growth hormone in the rat. Neuroendocrinology. 47:1988;498-503.
36. Rhee M.H., Bayewitch M., Avidor-Reiss T., Levy R., Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem. 71:1998;1217-1225.
37. Rodríguez de Fonseca F., Cebeira M., Ramos J.A., Martín M., Fernández-Ruiz J.J. Cannabinoid receptors in rat brain areas: sexual differences, fluctuations during estrous cycle and changes after gonadectomy and sex steroid replacement. Life Sci. 54:1993;159-170.
38. Rodríguez de Fonseca F., Villanúa M.A., Muñoz R.M., San Martin-Clarke O., Navarro M. Differential effects of chronic treatments with dopamine D-1 and D-2 receptor agonists on the acute neuroendocrine effects of the highly potent synthetic cannabinoid HU-210. Neuroendocrinology. 61:1995;714-721.
39. 2+ after transient elevations in clonal rat lactotrophs. Acta Physiol. Scand. 137:1989;113-123.
40. Steger R.W., De Paolo L.V., Asch R.H., Silverman A.Y. Interactions of delta-9-tetrahydrocannabinol (THC) with hypothalamic neurotransmitters controlling luteinizing hormone and prolactin release. Neuroendocrinology. 37:1983;361-370.
41. T. Wenger, E. Bácsy, K.A. Jamali, C. Juaneda, G. Tramu, J. Leonardelli, Does the endogenous cannabinoid system play a role in the regulation of anterior pituitary hormone secretion? An in vitro study. 1998 Symposium on the Cannabinoids, Montpellier, July 23-25, 1998. International Cannabinoid Research Society, Burlington, VT, USA, p. 60.
42. Wenger T., Khalid A.J., Juaneda C., Leonardelli J., Tramu G. Arachidonyl ethanolamide (anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 237:1997;724-728.